Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs

Coronary Artery Disease

Volumn 11, Issue 1, 2000, Pages 83-90

  Fukutomi, Takashi ^a   Satoh, Kumi ^b   Ogoshi, Shohei ^a   Ichihara, Kazuo ^b,c  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

ATP; EGIS 9377; Myocardial stunning; OG VI; Pimobendan

Indexed keywords

2 (1 METHYLTHIO) 5 (2 MORPHOLINOETHYLAMINO) 8,9 DINHYDRO 7H THIOPYRANO[3,2 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; CARDIOTONIC AGENT; OG VI; PENTOBARBITAL; PIMOBENDAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG EFFECT; FEMALE; HEART DISEASE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STUNNED HEART MUSCLE; TISSUE METABOLISM; VASCULAR RESISTANCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOGS; HEART; HEMODYNAMIC PROCESSES; MORPHOLINES; MYOCARDIAL REPERFUSION; MYOCARDIAL STUNNING; MYOCARDIUM; NUCLEOSIDES; NUCLEOTIDES; PYRIDAZINES; PYRIMIDINES;

EID: 0034052752     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200002000-00014     Document Type: Article

References (22)

1. 1 Rüegg JC, Pfitzer G, Eubler D, Zeugner C. Effect on contractility of skinned fibers from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone. Arzneimforsch/Drug Res 1984; 34:1736-1738.
2. 2+ activation and the inotropic effect of pímobendan: comparison with milrinone. Circ Res 1988; 63:911-922.
3. 3 Sholz H, Meyer W. Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation 1986; 73 (suppl III):III99-III108.
4. 4 Pouleur H, Gurné O, Hanet C, Balasim H, Mechelen HV, Charlier AA. Effects of pimobendan (UD-CG 115) on the contractile function of the normal and 'postischemia' canine myocardium. J Cardiovasc Pharmacol 1988; 11:100-106.
5. 5 Ichihara K, Abiko Y. The effect of pimobendan on myocardial mechanical function and metabolism in dogs: comparison with dobutamine. J Pharm Pharmacol 1991; 43:583-588.
6. 6 Remme WJ, Kruijssen DACM, Hoogenhuyze DCAV, Krauss XH, Bartels GL, Storm CJ, et al. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol 1994; 24:730-739.
7. 7 Japanese Patent, Hei 5-148267, 15 June, 1993.
8. 8 USA Patent, US5478825, 26 December, 1995.
9. 9 Ogoshi S, Iwasa M, Mizobuchi S, Iwasa Y, Martiz A, Tamiya T. Effect of a nucleoside and nucleotide mixture on protein metabolism in rats given total parenteral nutrition after 70% hepatectomy. In: Tanaka T, Okada A (editors): Nutritional support in organ failure. Amsterdam: Elsevier Science; 1990. pp. 309-317.
10. 10 Satoh K, Nakai T, Hoshi K, Ichihara K. Limitation of stunning in dog myocardium by nucleoside and nucleotide mixture, OG-VI. Coronary Artery Dis 1993; 4:1007-1012.
11. 11 Kano S, Nakai T, Kohri H, Ichihara K. Effects of OG-VI, a nucleoside/nucleotide mixture, and its constituents on myocardial stunning in dogs. Coronary Artery Dis 1995; 6:811-818.
12. 1 receptor involved? Coronary Artery Dis 1998; 9:29-34.
13. 13 Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium. J Cardiovasc Pharmacol 1991 ; 18 (suppl 10):S93-S101.
14. 14 Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the 'stunned myocardium'. Circ Res 1986; 58:148-156.
15. 15 Mashima H. Hemodynamics [in Japanese]. In: Mashima H (editor): Physiology. 18th ed. Tokyo: Bunkoudo; 1980. pp. 379-397.
16. 16 Ichihara K, Abiko Y. Difference between endocardial and epicardial utilization of glycogen in the ischemic heart. Am J Physiol 1975; 229:1585-1589.
17. 17 Bergmeyer HU (editor). Methods of enzymatic analysis. New York: Academic Press; 1974.
18. 18 Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66:1146-1149.
19. 19 Ehring T, Böhm M, Heusch G. The calcium antagonists nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia. J Cardiovasc Pharmacol 1992; 20:63-74.
20. 20 Von Corswant C, Thorén P, Engström S. Triglyceride-based microemulsion for intravenous administration of sparingly soluble substances. J Pharmacol Sci 1998; 87:200-208.
21. 21 Fujimoto S, Matsuda T. Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 1990; 252:1304-1311.
22. 22 Satoh K, Maruyama M, Taira N. The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog. Jap Heart J 1982; 23:975-980.